EU's CHMP OKs Major New Uses for Hemlibra, Praluent, Forxiga – And More
Executive Summary
Several major products have been recommended for wider indications in the EU, including Roche’s hemophilia drug Hemlibra, Sanofi’s Praluent in atherosclerotic disease, and AstraZeneca’s Forxiga for type 1 diabetes.